Guilford, Conn. — February 19, 2024 — InveniAI LLC, a global leader in the application of artificial intelligence (AI) and machine learning (ML) tools to revolutionize drug discovery and development, announces a strategic collaboration with Ono Pharmaceutical Co., Ltd. (Ono), a renowned pharmaceutical company committed to advancing innovative solutions for unmet medical needs.
Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono's diseases of interest. Ono will access InveniAI's AI platform AlphaMeld® and its suite of tools, including ChatAlphaMeld™, a generative AI tool leveraging large language models.
InveniAI's cutting-edge technology, including powerful AI and ML algorithms and Generative AI tools, powers its flagship platform AlphaMeld, which has consistently demonstrated the ability to unlock transformative therapies by seamlessly integrating complex scientific, medical, chemical, and biological landscapes at unprecedented speed and scale. Ono will conduct validation studies to confirm the hypotheses for multiple therapeutic target candidates identified based on InveniAI's drug discovery hypotheses. Ono will retain exclusive rights to develop and commercialize drug candidates generated through this collaboration worldwide.
"We appreciate InveniAI's proprietary AI and ML technologies to identify drug discovery mechanisms utilizing enormous amounts of data for the creation of innovative drugs," said Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono. "Through this collaboration, the efficiency of drug discovery research will be greatly improved, and we hope to provide innovative therapeutic options to patients worldwide."
"InveniAI is thrilled to partner with Ono, a company renowned for its commitment to innovation in drug discovery and development. Our collaboration signifies the merging of our collective expertise and cutting-edge technologies aimed at expediting the identification of de-risked product opportunities," said Krishnan Nandabalan, Ph.D., President and CEO at InveniAI, LLC.